Selective Sensing of Darolutamide and Thalidomide in Pharmaceutical Preparations and in Spiked Biofluids
November 2022
in “
Biosensors
”
TLDR A new, efficient method has been developed to detect darolutamide and thalidomide, drugs used for certain hair loss and prostate cancer treatments, in pharmaceuticals and body fluids.
The document introduces a new, cost-effective, and less time-consuming fluorescence sensing method for detecting darolutamide and thalidomide, drugs used in treating androgen-dependent diseases like androgenic alopecia and prostate cancer. The method involves the synthesis of a compound, 2,4,8,10-Tetramethylpyrido[2′,3′:3,4]Pyrazolo[1,5-a]Pyrimidine 2, which is used in the fluorescence sensing method. The fluorescence intensity of this compound is inversely proportional to the drug concentration, with the highest intensity observed at a pH of 7.2 and a reagent volume of 1.25 mL. The method was validated and found to be accurate, precise, and robust. It was successfully applied to pharmaceutical preparations and spiked biofluids, with satisfactory recovery percentages for darolutamide and thalidomide determination in raw material and dosage forms. This method can be used in quality control and bioavailability laboratories.
